Effect of Folic Acid and Vitamin B12 Supplementation in Subjects With Type 2 Diabetes
Diabetes Mellitus, Type 2
About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion Criteria:
- Type 2 Diabetic patients within age group 30-65 years, on stable dose of anti-diabetic with/without anti-hypertensive drugs will be included in this study
Exclusion Criteria:
- Subjects on non-allopathic forms of treatment for diabetic control.
- Subjects with Chronic Renal disease and Liver disease.
- Subjects with malabsorption.
- Subjects with Thyroid function abnormalities.
- HbA1c levels more than 10 %
- Smoking
- Alcoholism
- Pregnant subjects
- Subjects with vitamin B12 deficiency
- Subjects already on Folate or Vitamin B12 supplementation due to some other medical condition
- The detailed drug history of the subjects will be taken prior to including them in the study. Antibiotics like Fluoroquinolones; anti-seizure drugs like phenytoin; Corticosteroids and Hormonal Contraceptives; Hypolipidemic drugs like statins are known to affect Glucose metabolism and subjects on these medications will not be included in the study.
Sites / Locations
- All India Institute of Medical Sciences, Bhubaneswar
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Active Comparator
Folic acid
Vitamin B12
"Folic acid" and "Vitamin B12"
Control
Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive tab. Folic acid 5 mg once daily for 8 weeks
Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive tab. Vitamin B12 500 mcg once daily for 8 weeks
Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive both tab. Folic acid 5 mg once daily and tab. Vitamin B12 500 mcg once daily for 8 weeks
Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and receive no additional supplementation